COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00775840
Recruitment Status : Completed
First Posted : October 20, 2008
Last Update Posted : June 22, 2010
Information provided by:

Brief Summary:
The purpose of this study is to determine the effects of candesartan, once daily (QD), on the N-terminal pro-B-type Natriuretic Peptide laboratory marker in subjects with symptomatic heart failure with diastolic dysfunction.

Condition or disease Intervention/treatment Phase
Heart Failure Drug: Candesartan Drug: Placebo Phase 3

Detailed Description:

Heart diseases are the number one cause of death in developed countries and in particular chronic or congestive heart failure is the leading cause of hospitalization in patients older than 65 years. It is still increasing in prevalence and, in spite of significant advances in therapy, mortality rates remain high: 30% to 40% of patients with advanced disease, and 5% to 10% of patients with mild symptoms will die within 5 to 10 years.

A relevant proportion of the heart failure patients (30 - 50%) suffering from edema and dyspnea have normal or minimally impaired left ventricular ejection fraction (preserved left ventricular ejection fraction) with diastolic abnormalities in echocardiography. Features of diastolic dysfunction are the stiffness, the decreased compliance and the impaired relaxation of the left ventricle. As a result, the left ventricle has a limited filling capacity during a normal left atrial pressure.

Hypertension and/or diabetes are the most predisposing conditions whereas left ventricular hypertrophy is regarded as the linking intermediate pathological condition. Moreover, recent studies showed that patients with symptomatic heart failure and an ejection fraction greater than 40% have a poor prognosis with relatively high mortality and hospitalization rates. Thus, in hypertensive patients, diastolic dysfunction has shown to be a predictor of morbidity.

Diastolic dysfunction is also a frequent finding in type 2 diabetes without symptoms and signs of heart disease. As long as it is independent of ischemic heart disease, it is presumably due to diabetic cardiomyopathy. Once aggravated to heart failure, diastolic dysfunction often coexists with systolic dysfunction as a consequence of coronary artery disease with a limited coronary reserve.

This study will determine whether pharmacological intervention into the Renin Angiotensin Aldosterone System exerted by the Angiotensin-Receptor Blocker Candesartan on top of an Angiotensin-Converting Enzyme Inhibitor-based therapy may lead to a significant drop of N-terminal pro-B-type Natriuretic Peptide. This neurohormonal laboratory marker is sufficient enough to simultaneously indicate the improvement of the causing diastolic dysfunction and associated heart failure symptoms as assessed by objective echocardiographic and clinical parameters.

Total time for participants in this study is approximately 26 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Candesartan "Added" Therapy for Treatment Optimization of Symptomatic Heart Failure With Diastolic Dysfunction in Diabetic and Hypertensive Patients A Randomized, Placebo-controlled, Double-blind, Parallel-group and Multicenter Clinical Phase III Study Investigating the Effects on NT-proBNP Over 6 Months
Study Start Date : January 2008
Actual Primary Completion Date : December 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Experimental: Candesartan QD + Heart Failure Therapy
(with angiotensin-converting enzyme-inhibitors/beta-blockers)
Drug: Candesartan
Candesartan up to 32 mg, tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
Other Name: BLOPRESS®

Placebo Comparator: Placebo QD + Heart Failure Therapy
(with angiotensin-converting enzyme-inhibitors/beta-blockers)
Drug: Placebo
Candesartan matching-placebo tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.

Primary Outcome Measures :
  1. The change from Baseline in N-terminal pro-B-type Natriuretic Peptide biomarker. [ Time Frame: Week 24 or Final Visit. ]

Secondary Outcome Measures :
  1. Mean change in N-terminal pro-B-type Natriuretic Peptide (log-transformed). [ Time Frame: Weeks 6 and 24 or Final Visit. ]
  2. Change from Baseline in Short Form-36 Health Survey score. [ Time Frame: Week 24 or Final Visit. ]
  3. Change from Baseline in Cystatin C. [ Time Frame: Week 24 or Final Visit. ]
  4. Change from Baseline in Adiponectin. [ Time Frame: Week 24 or Final Visit. ]
  5. Change from Baseline in Glycosylated Hemoglobin. [ Time Frame: Week 24 or Final Visit. ]
  6. Change from Baseline in Urinary Albumin Excretion. [ Time Frame: Week 24 or Final Visit. ]
  7. Change from Baseline in estimated Glomerular Filtration Rate and Cystatin C. [ Time Frame: Week 24 or Final Visit. ]
  8. Mean Change in New York Heart Association classification results. [ Time Frame: Week 24 or Final Visit. ]
  9. Body Weight. [ Time Frame: Week 24 or Final Visit. ]
  10. Blood Pressure. [ Time Frame: Week 24 or Final Visit. ]
  11. Echocardiograms. [ Time Frame: Week 24 or Final Visit. ]
  12. Correlations of N-terminal pro-B-type Natriuretic Peptide with New York Heart Association Classification Results. [ Time Frame: Week 24 or Final Visit. ]
  13. Correlations of N-terminal pro-B-type Natriuretic Peptide with short Form-36 Health Survey Score. [ Time Frame: Week 24 or Final Visit. ]
  14. Correlations of N-terminal pro-B-type Natriuretic Peptide with Blood Pressure Results. [ Time Frame: Week 24 or Final Visit. ]
  15. Subgroup evaluations regarding beta-blocker therapy and New York Heart Association class (II/III). [ Time Frame: Week 24 or Final Visit. ]
  16. Subgroup evaluations in terms of the different possible dosages of study medication. [ Time Frame: Weeks 6 to 24 or Final Visit. ]
  17. Subgroup evaluations based on different baseline levels of estimated Glomerular Filtration Rate. [ Time Frame: Week 24 or Final Visit. ]
  18. Subgroup evaluations based on different baseline levels of Cystatin C. [ Time Frame: Week 24 or Final Visit. ]
  19. Subgroup evaluations based on different baseline levels of N-terminal pro-B-type Natriuretic Peptide. [ Time Frame: Week 24 or Final Visit. ]
  20. Comparison from Baseline on the concomitant use of Loop Diuretics. [ Time Frame: Weeks 6 and 24 or Final Visit. ]
  21. Transition from sinus rhythm to permanent atrial fibrillation based on electrocardiogram recordings. [ Time Frame: Week 24 or Final Visit. ]
  22. Progression of preserved (Left Ventricular Ejection Fraction greater than or equal to 45%) to impaired systolic dysfunction (Left Ventricular Ejection Fraction less than 45%), based on echocardiographic results. [ Time Frame: Week 24 or Final Visit. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diabetes mellitus type 2 - insulin dependent or orally treated or managed by diet for at least 3 Months.
  • Normotension or controlled hypertension with sitting Systolic Blood Pressure less than 140 mmHg and/or sitting Diastolic Blood Pressure less than 90 mmHg.
  • Regular sinus rhythm or atrial fibrillation with a medicamental-achieved rate control of less than 100 bpm as confirmed by electrocardiogram recordings.
  • Echocardiographic evidence of a preserved Left Ventricular Ejection Fraction greater than or equal to 45% (assessed by the modified Simpson method), with further doppler-echocardiographic criteria for diastolic dysfunction grade I-IV.
  • New York Heart Association classification of II or III in a stable condition since at least 3 months.
  • Existing background heart failure therapy with an Angiotensin-Converting Enzyme Inhibitor alone or together with further preparations in a constant regimen since at least 1 month, in case of beta-blockers since at least 3 months.
  • N-terminal pro-B-type Natriuretic Peptide greater than or equal to 250 pg/ml measured at screening visit or collected from a dated previous laboratory document not older than 3 months.
  • No previous therapy with Angiotensin-Receptor Blockers during the last 4 weeks prior to the study.
  • Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.

Exclusion Criteria:

  • Impaired renal function (serum creatinine greater than 2.2 mg/dl or greater than 194 μmol/l).
  • Known bilateral renal artery stenosis or interventional treatment for renal artery stenosis in the last year.
  • State after kidney transplantation.
  • Serum potassium greater than 5.5 mmol/l or glycosylated hemoglobin greater than 9.5 %.
  • Cor pulmonale or primary pulmonary disease with dyspnea at rest.
  • Known disposition to episodes of symptomatic hypotension or sitting Systolic Blood Pressure less than 95 mmHg at baseline.
  • Acute coronary syndrome or any form of unstable chronic Coronary Artery Disease where the indication of a coronary intervention is either planned in short or medium term or can not be clearly excluded for the period of the study.
  • Any history of: myocardial infarction, previous Percutaneous Transluminal Coronary Angioplasty with revascularization, stent implantation, Coronary Artery Bypass Graft or open heart surgery.
  • Tachycardia at rest greater than 100 bpm as confirmed by electrocardiogram recordings.
  • Known clinically relevant rhythm disorders (e.g., tachyarrhythmias, salves of supraventricular or ventricular extrasystoles or atrial fibrillation without ventricular rate control) or symptoms suggesting a significant rhythm disorder (e.g., recurrent syncopes).
  • Primary valvular diseases and/or restrictive or obstructive cardiomyopathy.
  • Existing ventricular assist devices.
  • Relevant liver diseases (cholestasis or alanine aminotransferase/aspartate aminotransferase greater than 2 times the upper limit of normal or gamma- glutamyltransferase greater than 3 times the upper limit of normal).
  • History of primary hyperaldosteronism, of cancer in the last 5 years or of another wasting disease with life expectancy of less than 2 years.
  • Known hypersensitivity to Candesartan Cilexetil.
  • Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

    • Need for maintenance therapy with Non-steroidal anti-inflammatory drugs or Cox-2-inhibitors.
    • Use of other Angiotensin-Receptor Blockers.
  • Any history of life-threatening diseases.
  • History of drug addiction and/or an extensive use of alcohol.
  • Acute coronary syndrome or unstable angina pectoris and any coronary artery disease that was not stable during the last 3 months prior to inclusion.
  • Patients who are dependent on a permanently paced pacemaker (i.e. a patient with a device that is not pacing during the echocardiographic examination can enter the study).
  • Open heart surgery for other reasons than coronary revascularization
  • Participation in another clinical investigation within 30 days prior to enrolment or for the course of the present study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00775840

Layout table for location information
Bad Friedrichshall, Baden-Württemberg, Germany
Heidelberg, Baden-Württemberg, Germany
Ludwigsburg, Baden-Württemberg, Germany
Bad Homburg, Hessen, Germany
Bad Nauheim, Hessen, Germany
Darmstadt, Hessen, Germany
Frankfurt, Hessen, Germany
Giessen, Hessen, Germany
Kassel, Hessen, Germany
Limburg, Hessen, Germany
Melsungen, Hessen, Germany
Mühlheim, Hessen, Germany
Wiesbaden, Hessen, Germany
Nienburg, Niedersachsen, Germany
Northeim, Niedersachsen, Germany
Weyhe, Niedersachsen, Germany
Essen, Nordrhein-Westfalen, Germany
Gelsenkirchen, Nordrhein-Westfalen, Germany
Gladbeck, Nordrhein-Westfalen, Germany
Langenfeld, Nordrhein-Westfalen, Germany
Paderborn, Nordrhein-Westfalen, Germany
Siegen, Nordrhein-Westfalen, Germany
Bad Kreuznach, Rheinland-Pfalz, Germany
Neukirchen, Saarland, Germany
Coswig, Sachsen-Anhalt, Germany
Dresden, Sachsen, Germany
Hartmannsdorf, Sachsen, Germany
Leipzig, Sachsen, Germany
Leisnig, Sachsen, Germany
Machem, Sachsen, Germany
Markkleeberg, Sachsen, Germany
Riesa, Sachsen, Germany
Wermsdorf, Sachsen, Germany
Erfurt, Thüringen, Germany
Jena, Thüringen, Germany
Nordhausen, Thüringen, Germany
Berlin, Germany
Sponsors and Collaborators
Layout table for investigator information
Study Director: Medical Director Takeda Pharma Gmbh, Aachen (Germany)
Layout table for additonal information
Responsible Party: Medical Director, Takeda Pharma Gmbh, Aachen (Germany) Identifier: NCT00775840    
Other Study ID Numbers: BLO K026
2007-003070-26 ( EudraCT Number )
D-CAN-546 ( Other Identifier: Takeda ID )
U1111-1113-9515 ( Registry Identifier: WHO )
First Posted: October 20, 2008    Key Record Dates
Last Update Posted: June 22, 2010
Last Verified: June 2010
Keywords provided by Takeda:
Cardiac Failure
Congestive Heart Failure
Drug Therapy
Diabetes Mellitus
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action